Nalaganje...
Risk of Tuberculosis Reactivation With Tofacitinib (CP-690550)
Individuals with latent tuberculosis infection (LTBI) live with a risk of reactivation, and several treatments for chronic inflammatory conditions are highly associated with such reactivation. A new Janus kinase inhibitor, tofacitinib (CP-690550), has shown promising results for treatment of inflamm...
Shranjeno v:
| Main Authors: | , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2012
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3415851/ https://ncbi.nlm.nih.gov/pubmed/22474037 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jis269 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|